Articles
There were a number of areas where we asked the forecast panelists questions specifically regarding oncology, and how the changing environment might relate to oncology pharmacists.
Defibrotide sodium (Defitelio) is now US Food and Drug Administration (FDA)-approved for children and adult patients with hepatic veno-occlusive disease (VOD) with added kidney or lung abnormalities following hematopoietic stem cell transplantation (HSCT). This drug is the first to be approved for patients with severe hepatic VOD.
Immediate-release opioid analgesics will now require boxed warnings regarding the serious risks for abuse, addiction, overdose, neonatal opioid withdrawal syndrome (NOWS), and death associated with the drugs, according to an announcement by the US Food and Drug Administration (FDA).
Crizotinib (Xalkori) has been approved for expanded use in patients with metastatic non−small-cell lung cancer (NSCLC) whose tumors have an ROS1 gene alteration, according to an announcement by the US Food and Drug Administration (FDA). The first and only approved treatment for this patient population, crizotinib blocks ROS1 protein activity in tumors, possibly preventing NSCLC from spreading.
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration.
Lung cancer is the leading cause of death from cancer worldwide, estimated to be responsible for nearly 1 in 5 cancer deaths in 2012 (1.59 million deaths, 19.4% of total cancer deaths). In the United States, lung cancer is the second most frequently diagnosed cancer, with an estimated 224,390 new cases in 2016, representing the leading cause of cancer death in Americans.
Jennifer Brown, MD, PhD, expanded upon the results of her and her colleagues’ study of the hepatotoxic effects of idelalisib, particularly as frontline treatment of younger patients with chronic lymphocytic leukemia, which was presented at the 57th American Society of Hematology Annual Meeting & Exposition.
William A. Zellmer, BPharm, MPH, discusses how the 4th edition of the American Society of Health-System Pharmacists (ASHP) Foundation’s Pharmacy Forecast serves to improve the effectiveness of leaders in hospital and health-system pharmacy practice.
The American Society of Health-System Pharmacists (ASHP) Foundation's Pharmacy Forecast, now in its fourth edition, serves to improve the effectiveness of leaders in hospital and health-system pharmacy practice.
Here is a review of study results of various medications being reported from different conferences.